Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1343-1348

  Noell, Susan ^a   Mayer, Daniel ^a   Strauss, Wolfgang S L ^b   Tatagiba, Marcos S ^a   Ritz, Rainer ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

C6 glioma; Fluorescence diagnosis; Hypericin; Malignant glioma

Indexed keywords

HYPERICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOFLUORESCENCE; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG SELECTIVITY; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; GLIOMA CELL; HEMISPHERE; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; MALE; NEOPLASM TRANSPLANTATION; PERYLENE; RATS; RATS, WISTAR;

EID: 79955013106     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.968     Document Type: Article

References (46)

1. Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol 472: 323-342, 2009.
2. Ammirati M, Vick N, Liao YL, Ciric I and Mikhael M: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21: 201-206, 1987. (Pubitemid 17131119)
3. Barker FG, Chang SM, Larson DA, Sneed PK, Wara WM, Wilson CB and Prados MD: Age and radiation response in glioblastoma multiforme. Neurosurgery 49: 1288-1297, 2001.
4. Bashir R, Hochberg F and Oot R: Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23: 27-30, 1988.
5. Brandes AA, Tosoni A, Franceschi E, et al: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27: 1275-1279, 2009.
6. Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 30: 10-14, 2003.
7. Davis FG, Freels S, Grutsch J, Barlas S and Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88: 1-10, 1998.
8. Ekinci G, Akpinar IN, Baltacioglu F, Erzen C, Kilic T, Elmaci I and Pamir N: Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence. Eur J Radiol 45: 99-107, 2003. (Pubitemid 36092129)
9. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001. (Pubitemid 32799739)
10. McGirt MJ, Chaichana KL, Gathinji M, et al: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110: 156-162, 2009.
11. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F and Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392-401, 2006.
12. Stummer W, Reulen HJ, Meinel T, et al: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62: 564-576, 2008.
13. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
14. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
15. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
16. Eljamel MS, Goodman C and Moseley H: ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci 23: 361-367, 2008.
17. Stepp H, Beck T, Pongratz T, Meinel T, Kreth FW, Tonn JC and Stummer W: ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 26: 157-164, 2007. (Pubitemid 47295558)
18. Stylli SS, Kaye AH, MacGregor L, Howes M and Rajendra P: Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 12: 389-398, 2005. (Pubitemid 40745222)
19. Stylli SS and Kaye AH: Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies. J Clin Neurosci 13: 709-717, 2006. (Pubitemid 44354170)
20. Dougherty TJ, Gomer CJ, Henderson BW, et al: Photodynamic therapy. J Natl Cancer Inst 90: 889-905, 1998. (Pubitemid 28304157)
21. Vandenbogaerde AL, Kamuhabwa A, Delaey E, Himpens BE, Merlevede WJ and De Witte PA: Photocytotoxic effect of pseudohypericin versus hypericin. J Photochem Photobiol B 45: 87-94, 1998. (Pubitemid 28550183)
22. Miccoli L, Beurdeley-Thomas A, De Pinieux G, Sureau F, Oudard S, Dutrillaux B and Poupon MF: Light-induced photo-activation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res 58: 5777-5786, 1998. (Pubitemid 29006419)
23. Lavie G, Kaplinsky C, Toren A, Aizman I, Meruelo D, Mazur Y and Mandel M: A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: possible relevance to photodynamic therapy. Br J Cancer 79: 423-432, 1999. (Pubitemid 29046214)
24. Kamuhabwa AA, Cosserat-Gerardin I, Didelon J, et al: Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. Int J Cancer 97: 253-260, 2002. (Pubitemid 34019963)
25. Couladis M, Badisa RB, Baziou P, Chaudhuri SK, Pilarinou E, Verykokidou E and Harvala C: Antioxidant and cytotoxic activities of Hypericum sp. on brine shrimps and human cancer cell lines. Phytother Res 16: 719-722, 2002. (Pubitemid 135752577)
26. Liu CD, Kwan D, Saxton RE and McFadden DW: Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res 93: 137-143, 2000.
27. Ritz R, Muller M, Weller M, Dietz K, Kuci S, Roser F and Tatagiba M: Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitro. Int J Oncol 27: 1543-1549, 2005.
28. Uzdensky AB, Bragin DE, Kolosov MS, Kubin A, Loew HG and Moan J: Photodynamic effect of hypericin and a water-soluble derivative on isolated crayfish neuron and surrounding glial cells. J Photochem Photobiol B 72: 27-33, 2003. (Pubitemid 37509032)
29. Wurglics M and Schubert-Zsilavecz M: Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45: 449-468, 2006.
30. Caccia S and Gobbi M: St. John's wort components and the brain: uptake, concentrations reached and the mechanisms underlying pharmacological effects. Curr Drug Metab 10: 1055-1065, 2009.
31. Paulke A, Schubert-Zsilavecz M and Wurglics M: Determination of hypericin and pseudohypericin from Hypericum perforatum in rat brain after oral administration. Monatsh Chem 139: 489-494, 2008.
32. Van De Putte M, Roskams T, Bormans G, Verbruggen A and De Witte PA: The impact of aggregation on the biodistribution of hypericin. Int J Oncol 28: 655-660, 2006.
33. Saller R, Melzer J and Reichling J: [St. John's Wort (Hypericum perforatum): a plurivalent raw material for traditional and modern therapies]. Forsch Komplementarmed Klass Naturheilkd 10 (Suppl 1): 33-40, 2003.
34. Fox E, Murphy RF, McCully CL and Adamson PC: Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 47: 41-44, 2001. (Pubitemid 32664511)
35. Pardridge WM: Molecular biology of the blood-brain barrier. Mol Biotechnol 30: 57-70, 2005.
36. Chung PS, Saxton RE, Paiva MB, et al: Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope 104: 1471-1476, 1994. (Pubitemid 24374594)
37. Du HY, Bay BH and Olivo M: Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model. Int J Oncol 22: 1019-1024, 2003.
38. Xie X, Hudson JB and Guns ES: Tumor-specific and photo-dependent cytotoxicity of hypericin in the human LNCaP prostate tumor model. Photochem Photobiol 74: 221-225, 2001.
39. Zupko I, Kamuhabwa AR, D'Hallewin MA, Baert L and De Witte PA: In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors. Int J Oncol 18: 1099-1105, 2001.
40. Kabuto M, Kubota T, Kobayashi H, et al: Experimental and clinical study of detection of glioma at surgery using fluorescent imaging by a surgical microscope after fluorescein administration. Neurol Res 19: 9-16, 1997. (Pubitemid 27143654)
41. Madsen SJ, Angell-Petersen E, Spetalen S, Carper SW, Ziegler SA and Hirschberg H: Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med 38: 540-548, 2006.
42. Angell-Petersen E, Spetalen S, Madsen SJ, et al: Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J Neurosurg 104: 109-117, 2006.
43. Stummer W, Stocker S, Novotny A, et al: In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B 45: 160-169, 1998.
44. Kostron H: Photodynamische Therapie in der Neurochirurgie. In: Klinische Fluoreszenzdiagnostik Und Photodynamische Therapie. 1st edition. Szeimies RM, Jocham D and Landthaler M (eds). Blackwell Verlag GmbH, Berlin, pp299-322, 2003.
45. Kaye AH and Hill JS: Photodynamic therapy of brain tumours. Ann Acad Med Singapore 22: 470-481, 1993.
46. Obwegeser A, Jakober R and Kostron H: Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenyl chlorin and 5-aminolaevulinic acid in the C6 rat glioma model. Br J Cancer 78: 733-738, 1998. (Pubitemid 28418304)